New Prescriber's Guide Details Oral Ketamine Protocol

A New Clinical Reference for Oral Ketamine Dosing

Psychiatrist.com published "The Prescriber's Guide to Oral Ketamine for Patients With Major Depressive Illness: Principles and Practice" on August 26, 2026. According to the publisher's description, the guide explains the clinical contexts in which oral ketamine can be used and presents a detailed protocol for the intervention. Oral ketamine refers to ketamine administered by mouth, typically as a compounded liquid, troche, or tablet, as opposed to intravenous (IV) infusion, intramuscular (IM) injection, or intranasal esketamine (Spravato), which is FDA-approved specifically for treatment-resistant depression.

The article is framed as a practice-oriented resource for prescribers rather than a new clinical trial, and the source description does not specify the dosing ranges, monitoring intervals, or patient-selection criteria the guide recommends. Readers who want the specific protocol details should consult the original article directly, since we have not reviewed its full text here.

Why Oral Ketamine Guidance Matters Right Now

Oral ketamine occupies a distinct niche in the depression treatment landscape. Unlike IV ketamine, which requires infusion clinic infrastructure and direct medical supervision during dosing, oral formulations are more often used in outpatient or take-home settings, frequently as maintenance therapy following an initial series of IV or IM sessions. This lower barrier to access is also what makes oral ketamine's variability in bioavailability, dosing consistency, and monitoring practices a persistent area of clinical discussion.

Ketamine's oral bioavailability is lower and more variable than IV or IM routes because of extensive first-pass liver metabolism, which converts a substantial portion of the dose into norketamine before it reaches systemic circulation. This pharmacokinetic reality is one reason formal prescriber guidance matters: without a structured protocol, dosing decisions for oral ketamine can vary significantly between prescribers, potentially affecting both efficacy and the ability to track a patient's response over time.

What This Means For Readers Considering or Using Oral Ketamine

For readers who are patients, caregivers, or clinicians researching low-dose ketamine therapy, a published, protocol-level guide is a useful reference point when evaluating whether a prescriber's approach reflects an established framework rather than an ad hoc regimen. That said, the value of this guide depends heavily on its underlying evidence base, which the available summary does not detail. Readers should look specifically at whether the protocol distinguishes between induction phases and maintenance dosing, since these typically involve different frequencies and target doses.

Consider these practical questions when discussing oral ketamine with a prescriber:

1. What is the source and rationale for the specific dose and frequency being recommended, and how does it compare to published protocols like this one?
2. What baseline and ongoing monitoring is planned, particularly for blood pressure, dissociative side effects, and signs of problematic use, given ketamine's abuse potential and Schedule III controlled-substance status in the United States?
3. How will treatment response be measured over time, and what is the plan if the initial dose is ineffective or poorly tolerated?
4. Is the oral formulation compounded by a licensed pharmacy, and what quality-control measures are in place given that compounded ketamine products are not FDA-approved in the way esketamine nasal spray is?

None of these questions imply that oral ketamine prescribing is inherently problematic. Off-label prescribing is a legal and common practice in psychiatry, and ketamine has an expanding evidence base for depression when used under appropriate supervision. The point of a structured guide like this one is to help standardize practice, which is generally a positive development for patient safety and consistency of care.

Where the Evidence Still Needs to Catch Up

Oral ketamine has less robust clinical trial data behind it compared to IV ketamine or intranasal esketamine, which carries FDA approval specifically for treatment-resistant depression based on randomized controlled trials submitted to the agency. Much of the current oral ketamine literature consists of smaller studies, open-label trials, and case series, which is a meaningful limitation when interpreting any new protocol. A prescriber's guide can still be clinically useful by synthesizing available evidence and expert consensus into a practical framework, but readers should understand that "detailed protocol" does not necessarily mean "large randomized trial-backed."

We'll continue to track developments in oral ketamine research and guidance as they're published, since protocol standardization is one of the more consequential trends shaping how this treatment is delivered outside hospital and infusion-clinic settings.